Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin

Journal of Nuclear Medicine

Volumn 54, Issue 5, 2013, Pages 762-769

  Dumont, Rebecca A ^a,b   Tamma, MariaLuisa ^c   Braun, Friederike ^a   Borkowski, Sandra ^d   Reubi, Jean Claude ^e   Maecke, Helmut ^a,c   Weber, Wolfgang A ^a   Mansi, Rosalba ^a,c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d BAYER PHARMA AG   (Germany)

^e UNIVERSITY OF BERN   (Switzerland)

Author keywords

Bombesin antagonist; Combination therapy; Prostate cancer; Radiopeptide therapy

Indexed keywords

BAY 1017858; GALLIUM 68; GASTRIN RELEASING PEPTIDE RECEPTOR; GASTRIN RELEASING PEPTIDE RECEPTOR ANTAGONIST; LUTETIUM 177; RADIOPHARMACEUTICAL AGENT; RAPAMYCIN; RM 2 LU 177; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TARGETING; DRUG UPTAKE; FEMALE; GAMMA CAMERA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

BOMBESIN ANTAGONIST; COMBINATION THERAPY; PROSTATE CANCER; RADIOPEPTIDE THERAPY;

ANIMALS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUTETIUM; MALE; MICE; MOLECULAR TARGETED THERAPY; OLIGOPEPTIDES; PROSTATIC NEOPLASMS; RADIOISOTOPES; RECEPTORS, BOMBESIN; SIROLIMUS;

EID: 84877131430     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.112169     Document Type: Article

References (42)

1. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 2005;23:8253-8261. (Pubitemid 46211563)
2. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512. (Pubitemid 39315317)
3. Figg WD, Arlen P, Gulley J, et al. A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Semin Oncol. 2001;28:62-66. (Pubitemid 32947554)
4. Amato RJ, Sarao H. A phase I study of paclitaxel/doxorubicin/thalidomide in patients with androgen-independent prostate cancer. Clin Genitourin Cancer. 2006;4:281-286. (Pubitemid 43779886)
5. Amato RJ, Jac J, Mohammad T, Saxena S. Pilot study of rapamycin in patients with hormone-refractory prostate cancer. Clin Genitourin Cancer. 2008;6:97-102.
6. Yu EY, Massard C, Gross ME, et al. Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology. 2011;77:1166-1171.
7. McCall P, Witton CJ, Grimsley S, Nielsen KV, Edwards J. Is PTEN loss associated with clinical outcome measures in human prostate cancer? Br J Cancer. 2008;99:1296-1301.
8. Shukla S, Maclennan GT, Hartman DJ, Fu P, Resnick MI, Gupta S. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int J Cancer. 2007;121:1424-1432. (Pubitemid 47328700)
9. Guba M, Koehl GE, Neppl E, et al. Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer. Transpl Int. 2005;18:89-94. (Pubitemid 41742951)
10. Guba M, Yezhelyev M, Eichhorn ME, et al. Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. Blood. 2005;105:4463-4469. (Pubitemid 40720795)
11. Konings IR, Verweij J, Wiemer EA, Sleijfer S. The applicability of mTOR inhibition in solid tumors. Curr Cancer Drug Targets. 2009;9:439-450.
12. Cao C, Subhawong T, Albert JM, et al. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res. 2006;66:10040-10047. (Pubitemid 44672057)
13. 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. J Nucl Med. 2004;45:1390-1397.
14. 68Ga-labeled peptides in tumor imaging. J Nucl Med. 2005;46(suppl 1):172S-178S.
15. Van de Wiele C, Dumont F, Vanden Broecke R, et al. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur J Nucl Med. 2000;27:1694-1699.
16. Zhang H, Chen J, Waldherr C, et al. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer Res. 2004;64:6707-6715. (Pubitemid 39302601)
17. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24:389-427. (Pubitemid 37056239)
18. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res. 1999;59:1152-1159. (Pubitemid 29135980)
19. Garrison JC, Rold TL, Sieckman GL, et al. In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems. J Nucl Med. 2007;48:1327-1337. (Pubitemid 47242799)
20. Lears KA, Ferdani R, Liang K, et al. In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer. J Nucl Med. 2011;52:470-477.
21. 111In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med. 2002;43:1650-1656.
22. 64Cu-NOTA-8-Aoc- BBN(7-14) NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proc Natl Acad Sci USA. 2007;104:12462-12467.
23. 99mTc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignancies. J Nucl Med. 2001;42:1722-1727.
24. 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med. 2006;47:1144-1152.
25. 177Lu-AMBA Bombesin analogue in hormone refractory prostate cancer patients: a phase I escalation study with single-cycle administrations. Paper presented at: Annual Congress, European Association of Nuclear Medicine; Oct 13-17, 2007; Copenhagen, Denmark
26. Mansi R, Wang X, Forrer F, et al. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging. 2011;38:97-107.
27. Mansi R, Wang X, Forrer F, et al. Evaluation of a 1,4,7,10- tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides. Clin Cancer Res. 2009;15:5240-5249.
28. Dobrowsky W, Huigol NG, Jayatilake RS, et al. AK-2123 (Sanazol) as a radiation sensitizer in the treatment of stage III cancer cervix: initial results of an IAEA multicentre randomized trial. J Cancer Res Ther. 2005;1:75-78. (Pubitemid 41265232)
29. Riahi Idrissi H, Chargari C, Bollet MA, et al. Concurrent whole-brain radiotherapy with trastuzumab for treatment of brain metastases in breast cancer patients: questions and answers. Bull Cancer. 2011;98:425-432.
30. Tejani MA, Cohen RB, Mehra R. The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer. Biologics. 2010;4:173-185.
31. 68Ga for medical application. J Nucl Med. 2007;48:1741-1748.
32. Yuan J. Estimation of variance for AUC in animal studies. J Pharm Sci. 1993;82:761-763. (Pubitemid 23315700)
33. 177Lu-DOTA-8-AOC-BBN (7-14)NH(2) GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice. Cancer Biother Radiopharm. 2006;21:155-166.
34. Pourmand G, Ziaee AA, Abedi AR, et al. Role of PTEN gene in progression of prostate cancer. Urol J. 2007;4:95-100.
35. Manegold PC, Paringer C, Kulka U, et al. Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer. Clin Cancer Res. 2008;14:892-900. (Pubitemid 351231174)
36. Shinohara ET, Cao C, Niermann K, et al. Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene. 2005;24:5414-5422. (Pubitemid 43080085)
37. Bridges KA, Hirai H, Buser CA, et al. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin Cancer Res. 2011;17:5638-5648.
38. Konsoula Z, Cao H, Velena A, Jung M. Adamantanyl-histone deacetylase inhibitor H6CAHA exhibits favorable pharmacokinetics and augments prostate cancer radiation sensitivity. Int J Radiat Oncol Biol Phys. 2011;79:1541-1548.
39. Moretti L, Niermann K, Schleicher S, et al. MLN8054, a small molecule inhibitor of aurora kinase a, sensitizes androgen-resistant prostate cancer to radiation. Int J Radiat Oncol Biol Phys. 2011;80:1189-1197.
40. Pchejetski D, Bohler T, Brizuela L, et al. FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1. Cancer Res. 2010;70:8651-8661.
41. Rudner J, Ruiner CE, Handrick R, Eibl HJ, Belka C, Jendrossek V. The Akt-inhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation. Radiat Oncol. 2010;5:108.
42. 177Lu-CHX-A″-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy. Prostate. 2009;69:92-104.